Citadel Advisors’s ProQR Therapeutics PRQR Stock Holding History
Bought
Maintained
Sold
Other funds holding PRQR
6CM
KCM
LCM
Citadel Advisors's PRQR Position: Q3 2026 in Review
Citadel Advisors reduced its ProQR Therapeutics (PRQR) stake by 28% in Q3 2026, selling an estimated $621K and leaving 856,295 shares worth $1.42M. The position accounts for ﹤0.01% of the portfolio, ranked #7595.
Citadel Advisors first reported a position in PRQR in Q3 2014 and has held it in 28 quarters since. The position peaked at $2.2M in Q2 2026. 73 funds tracked by Wall St. Rank hold PRQR as of Q3 2026.
- Citadel Advisors held 856,295 shares of ProQR Therapeutics worth $1.42M as of Q3 2026.
- Citadel Advisors sold 328,019 ProQR Therapeutics shares in Q3 2026, an estimated $621K.
- ProQR Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q3 2026, its #7595 holding.
- Citadel Advisors first reported a position in ProQR Therapeutics in Q3 2014 and has held it in 28 quarters since.
- Citadel Advisors's ProQR Therapeutics position peaked at $2.2M in Q2 2026.
- 73 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q3 2026.
Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.